Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis
- PMID: 28166427
- DOI: 10.1080/03007995.2017.1292230
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis
Abstract
Background: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS have shown inconsistent findings. This study aimed to assess the combined effect of B. infantis on reducing the symptom severity of IBS based on the published data.
Methods: A meta-analysis was conducted using fixed-effect models to estimate the combined effect of B. infantis on primary outcomes, which included abdominal pain, bloating/distention, and bowel habit satisfaction. A systematic review was performed based on PubMed, Cochrane Library, and EMBASE databases to identify the randomized controlled trials comparing probiotic B. infantis with placebo in treating IBS symptoms, published up until 31 December 2016. The standardized mean difference (SMD) method was used to combine data since scales to measure the efficacy of probiotics were different among studies.
Results: A total of five studies were identified as suitable for inclusion, including three studies with single probiotic B. infantis and two studies with composite probiotics containing B. infantis. Treatment with single probiotic B. infantis didn't impact on abdominal pain, bloating/distention, or bowel habit satisfaction among IBS patients. However, patients who received composite probiotics containing B. infantis had significantly reduced abdominal pain (SMD, 0.22; 95% CI, 0.03-0.41) and bloating/distention (SMD, 0.30; 95% CI, 0.04-0.56). After combining the data from six studies, the improvement of bloating/distention among IBS patients remained significant (SMD, 0.21; 95% CI, 0.07-0.35).
Conclusion: Composite probiotics containing B. infantis might be an effective therapeutic option for IBS patients, which could significantly alleviate the symptoms of IBS without significant adverse effects. However, the efficacy of single probiotic B. infantis on IBS has not been confirmed yet, which needs to be further validated by more large-sized randomized clinical trials.
Keywords: Bifidobacterium infantis 35624; irritable bowel syndrome; meta-analysis; probiotic.
Comment in
-
Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms.Curr Med Res Opin. 2017 Jul;33(7):1349-1351. doi: 10.1080/03007995.2017.1322571. Epub 2017 May 19. Curr Med Res Opin. 2017. PMID: 28436237 No abstract available.
-
Probiotic nomenclature matters redux: confusion on Bifidobacterium longum subsp. infantis taxonomy persists.Curr Med Res Opin. 2017 Nov;33(11):2097. doi: 10.1080/03007995.2017.1359153. Epub 2017 Aug 16. Curr Med Res Opin. 2017. PMID: 28812376 No abstract available.
Similar articles
-
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.Am J Gastroenterol. 2006 Jul;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x. Am J Gastroenterol. 2006. PMID: 16863564 Clinical Trial.
-
Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.Am J Gastroenterol. 2017 Jan;112(1):145-151. doi: 10.1038/ajg.2016.511. Epub 2016 Nov 15. Am J Gastroenterol. 2017. PMID: 27845337 Clinical Trial.
-
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis.Rev Esp Enferm Dig. 2013 Jan;105(1):19-36. doi: 10.4321/s1130-01082013000100005. Rev Esp Enferm Dig. 2013. PMID: 23548007
-
Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072. World J Gastroenterol. 2015. PMID: 25780308 Free PMC article. Review.
-
The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050. doi: 10.1038/ajg.2009.25. Epub 2009 Mar 10. Am J Gastroenterol. 2009. PMID: 19277023 Review.
Cited by
-
The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties.Microorganisms. 2024 Jan 23;12(2):234. doi: 10.3390/microorganisms12020234. Microorganisms. 2024. PMID: 38399637 Free PMC article. Review.
-
Metabolic model-based ecological modeling for probiotic design.Elife. 2024 Feb 21;13:e83690. doi: 10.7554/eLife.83690. Elife. 2024. PMID: 38380900 Free PMC article.
-
Supplementation With Bifidobacterium and Symptomatic Control in Irritable Bowel Syndrome: An Evidence-Based Review.Cureus. 2023 Aug 31;15(8):e44447. doi: 10.7759/cureus.44447. eCollection 2023 Aug. Cureus. 2023. PMID: 37791169 Free PMC article. Review.
-
Intestinal barrier dysfunction as a key driver of severe COVID-19.World J Virol. 2023 Mar 25;12(2):68-90. doi: 10.5501/wjv.v12.i2.68. World J Virol. 2023. PMID: 37033148 Free PMC article. Review.
-
Taxonomy Informed Clustering, an Optimized Method for Purer and More Informative Clusters in Diversity Analysis and Microbiome Profiling.Front Bioinform. 2022 Apr 27;2:864597. doi: 10.3389/fbinf.2022.864597. eCollection 2022. Front Bioinform. 2022. PMID: 36304326 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical